Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + Chemotherapy or SHR-8068 in dMMR/MSI-H Gastric/GEJ Adenocarcinoma
NCT07266025Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2026
- Primary completion
- Jun 2030
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07266025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266025.